To revolutionize global mental healthcare, we harness the power of naturally-sourced Psilocybin, producing cutting-edge products tailored for pharmaceutical applications, to effectively address the world's pressing health needs
MSICS operates an innovative GMP production facility producing MSX-06 - MSICS's flagship naturally-sourced Psilocybin product
MSX-06 is currently undergoing trials in collaboration with renowned hospitals, to treat medical conditions such as depression, OCD, anxiety, and eating disorders
We are currently recruiting patients for selected groundbreaking psilocybin-based clinical trials, in depression, OCD, anorexia, and PTSD
MSICS Pharma invites researchers and clinicians to submit proposals on psilocybin-based studies for PTSD treatment funding and GMP-grade psilocybin (MSX-06) will be provided to selected projects
Deadline Extended: Due to the strong interest, the submission deadline is now November 20, 2025
